Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

Overview of attention for article published in Blood, July 2011

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,119 followers.

$KURA Rationale for using tipi in PTCL came from this study https://t.co/14MKDDKO4T Went after r/r lymphomas & post-hoc showed PTCL did best

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients... http://t.co/iUhG56ZX #bloodTCB

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.